Delving into the Latest Updates on LY-4065967 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LY 4065967, LY4065967

Target

AT2R

Action

antagonists

Mechanism

AT2R antagonists(Angiotensin II receptor type 2 antagonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Low Back PainChronic PainDiabetic peripheral neuropathic pain

Inactive Indication-

Originator Organization

Eli Lilly & Co.

Active Organization

Eli Lilly & Co.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.

Start Date03 Jun 2026

Sponsor / Collaborator

Eli Lilly & Co.

NCT07285018

/ RecruitingPhase 2

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Diabetic Peripheral Neuropathic Pain

The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Start Date16 Feb 2026

Sponsor / Collaborator

Eli Lilly & Co.

NCT07039045

/ CompletedPhase 1

A Phase 1, Open-label, 2-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [14C]-LY4065967 in Healthy Male Participants

The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study. The study will last about 58 days for participants in Part 1 and about 60 days for participants in Part 2.

Start Date23 Jun 2025

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with LY-4065967

Login to view more data

100 Translational Medicine associated with LY-4065967

Login to view more data

100 Patents (Medical) associated with LY-4065967

Login to view more data

100 Deals associated with LY-4065967

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 2	United States	Eli Lilly & Co.	12 Aug 2026
Chronic Pain	Phase 2	United States	Eli Lilly & Co.	16 Feb 2026
Diabetic peripheral neuropathic pain	Phase 2	United States	Eli Lilly & Co.	16 Feb 2026